These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

274 related items for PubMed ID: 27235164

  • 1. Combination of Eribulin and Aurora A Inhibitor MLN8237 Prevents Metastatic Colonization and Induces Cytotoxic Autophagy in Breast Cancer.
    Kozyreva VK, Kiseleva AA, Ice RJ, Jones BC, Loskutov YV, Matalkah F, Smolkin MB, Marinak K, Livengood RH, Salkeni MA, Wen S, Hazard HW, Layne GP, Walsh CM, Cantrell PS, Kilby GW, Mahavadi S, Shah N, Pugacheva EN.
    Mol Cancer Ther; 2016 Aug; 15(8):1809-22. PubMed ID: 27235164
    [Abstract] [Full Text] [Related]

  • 2. Concurrent Inhibition of Neurosphere and Monolayer Cells of Pediatric Glioblastoma by Aurora A Inhibitor MLN8237 Predicted Survival Extension in PDOX Models.
    Kogiso M, Qi L, Braun FK, Injac SG, Zhang L, Du Y, Zhang H, Lin FY, Zhao S, Lindsay H, Su JM, Baxter PA, Adesina AM, Liao D, Qian MG, Berg S, Muscal JA, Li XN.
    Clin Cancer Res; 2018 May 01; 24(9):2159-2170. PubMed ID: 29463553
    [Abstract] [Full Text] [Related]

  • 3. The investigational Aurora kinase A inhibitor alisertib (MLN8237) induces cell cycle G2/M arrest, apoptosis, and autophagy via p38 MAPK and Akt/mTOR signaling pathways in human breast cancer cells.
    Li JP, Yang YX, Liu QL, Pan ST, He ZX, Zhang X, Yang T, Chen XW, Wang D, Qiu JX, Zhou SF.
    Drug Des Devel Ther; 2015 May 01; 9():1627-52. PubMed ID: 25834401
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of mitotic Aurora kinase A by alisertib induces apoptosis and autophagy of human gastric cancer AGS and NCI-N78 cells.
    Yuan CX, Zhou ZW, Yang YX, He ZX, Zhang X, Wang D, Yang T, Wang NJ, Zhao RJ, Zhou SF.
    Drug Des Devel Ther; 2015 May 01; 9():487-508. PubMed ID: 25609923
    [Abstract] [Full Text] [Related]

  • 5. Aurora kinase A mediates epithelial ovarian cancer cell migration and adhesion.
    Do TV, Xiao F, Bickel LE, Klein-Szanto AJ, Pathak HB, Hua X, Howe C, O'Brien SW, Maglaty M, Ecsedy JA, Litwin S, Golemis EA, Schilder RJ, Godwin AK, Connolly DC.
    Oncogene; 2014 Jan 30; 33(5):539-49. PubMed ID: 23334327
    [Abstract] [Full Text] [Related]

  • 6. c-Myc Is a Major Determinant for Antitumor Activity of Aurora A Kinase Inhibitor MLN8237 in Thyroid Cancer.
    Li Y, Li X, Pu J, Yang Q, Guan H, Ji M, Shi B, Chen M, Hou P.
    Thyroid; 2018 Dec 30; 28(12):1642-1654. PubMed ID: 30226440
    [Abstract] [Full Text] [Related]

  • 7. Inhibition of Aurora A Kinase in Combination with Chemotherapy Induces Synthetic Lethality and Overcomes Chemoresistance in Myc-Overexpressing Lymphoma.
    Park SI, Lin CP, Ren N, Angus SP, Dittmer DP, Foote M, Parton T, Bhatt AP, Fedoriw YD, Roth DP, Cann ML, Johnson GL, Damania B.
    Target Oncol; 2019 Oct 30; 14(5):563-575. PubMed ID: 31429028
    [Abstract] [Full Text] [Related]

  • 8. Polymer Nanovesicle-Mediated Delivery of MLN8237 Preferentially Inhibits Aurora Kinase A To Target RalA and Anchorage-Independent Growth in Breast Cancer Cells.
    Inchanalkar S, Deshpande NU, Kasherwal V, Jayakannan M, Balasubramanian N.
    Mol Pharm; 2018 Aug 06; 15(8):3046-3059. PubMed ID: 29863884
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of Copanlisib in Combination with Eribulin in Triple-negative Breast Cancer Patient-derived Xenograft Models.
    Guo Z, Luo J, Mashl RJ, Hoog J, Maiti P, Fettig N, Davies SR, Aft R, Held JM, Govindan R, Ding L, Li S, von Morze C, Wulf GM, Shoghi KI, Ma CX.
    Cancer Res Commun; 2024 Jun 05; 4(6):1430-1440. PubMed ID: 38717161
    [Abstract] [Full Text] [Related]

  • 10. Alisertib, an Aurora kinase A inhibitor, induces apoptosis and autophagy but inhibits epithelial to mesenchymal transition in human epithelial ovarian cancer cells.
    Ding YH, Zhou ZW, Ha CF, Zhang XY, Pan ST, He ZX, Edelman JL, Wang D, Yang YX, Zhang X, Duan W, Yang T, Qiu JX, Zhou SF.
    Drug Des Devel Ther; 2015 Jun 05; 9():425-64. PubMed ID: 25624750
    [Abstract] [Full Text] [Related]

  • 11. The histone deacetylase inhibitor OBP-801 and eribulin synergistically inhibit the growth of triple-negative breast cancer cells with the suppression of survivin, Bcl-xL, and the MAPK pathway.
    Ono H, Sowa Y, Horinaka M, Iizumi Y, Watanabe M, Morita M, Nishimoto E, Taguchi T, Sakai T.
    Breast Cancer Res Treat; 2018 Aug 05; 171(1):43-52. PubMed ID: 29752686
    [Abstract] [Full Text] [Related]

  • 12. Inhibition of Aurora A enhances radiosensitivity in selected lung cancer cell lines.
    Liu N, Wang YA, Sun Y, Ecsedy J, Sun J, Li X, Wang P.
    Respir Res; 2019 Oct 23; 20(1):230. PubMed ID: 31647033
    [Abstract] [Full Text] [Related]

  • 13. The investigational Aurora kinase A inhibitor MLN8237 induces defects in cell viability and cell-cycle progression in malignant bladder cancer cells in vitro and in vivo.
    Zhou N, Singh K, Mir MC, Parker Y, Lindner D, Dreicer R, Ecsedy JA, Zhang Z, Teh BT, Almasan A, Hansel DE.
    Clin Cancer Res; 2013 Apr 01; 19(7):1717-28. PubMed ID: 23403633
    [Abstract] [Full Text] [Related]

  • 14. A novel orally available seleno-purine molecule suppresses triple-negative breast cancer cell proliferation and progression to metastasis by inducing cytostatic autophagy.
    Chang CH, Bijian K, Wernic D, Su J, da Silva SD, Yu H, Qiu D, Asslan M, Alaoui-Jamali MA.
    Autophagy; 2019 Aug 01; 15(8):1376-1390. PubMed ID: 30773992
    [Abstract] [Full Text] [Related]

  • 15. The aurora kinase A inhibitor MLN8237 enhances cisplatin-induced cell death in esophageal adenocarcinoma cells.
    Sehdev V, Peng D, Soutto M, Washington MK, Revetta F, Ecsedy J, Zaika A, Rau TT, Schneider-Stock R, Belkhiri A, El-Rifai W.
    Mol Cancer Ther; 2012 Mar 01; 11(3):763-74. PubMed ID: 22302096
    [Abstract] [Full Text] [Related]

  • 16. A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma.
    Görgün G, Calabrese E, Hideshima T, Ecsedy J, Perrone G, Mani M, Ikeda H, Bianchi G, Hu Y, Cirstea D, Santo L, Tai YT, Nahar S, Zheng M, Bandi M, Carrasco RD, Raje N, Munshi N, Richardson P, Anderson KC.
    Blood; 2010 Jun 24; 115(25):5202-13. PubMed ID: 20382844
    [Abstract] [Full Text] [Related]

  • 17. Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP).
    Maris JM, Morton CL, Gorlick R, Kolb EA, Lock R, Carol H, Keir ST, Reynolds CP, Kang MH, Wu J, Smith MA, Houghton PJ.
    Pediatr Blood Cancer; 2010 Jul 15; 55(1):26-34. PubMed ID: 20108338
    [Abstract] [Full Text] [Related]

  • 18. Combined inhibition of Aurora A and p21-activated kinase 1 as a new treatment strategy in breast cancer.
    Korobeynikov V, Borakove M, Feng Y, Wuest WM, Koval AB, Nikonova AS, Serebriiskii I, Chernoff J, Borges VF, Golemis EA, Shagisultanova E.
    Breast Cancer Res Treat; 2019 Sep 15; 177(2):369-382. PubMed ID: 31254157
    [Abstract] [Full Text] [Related]

  • 19. Expression profile‑driven discovery of AURKA as a treatment target for liposarcoma.
    Yen CC, Chen SC, Hung GY, Wu PK, Chua WY, Lin YC, Yen CH, Chen YC, Wang JY, Yang MH, Chao Y, Chang MC, Chen WM.
    Int J Oncol; 2019 Oct 15; 55(4):938-948. PubMed ID: 31485600
    [Abstract] [Full Text] [Related]

  • 20. Alisertib (MLN8237), a selective Aurora-A kinase inhibitor, induces apoptosis in human tongue squamous cell carcinoma cell both in vitro and in vivo.
    Qi L, Zhang Y.
    Tumour Biol; 2015 Mar 15; 36(3):1797-802. PubMed ID: 25366143
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.